Use of genetically encoded, light-gated ion translocators to control tumorigenesis

The stages selected for the antineoplastic drugs mirror those of the light treatment. Embryos with ITLS between St. 28–35 were selected, treated with the drugs, and scored for ITLS between St. 45–47. Concentration of the drugs and their effects on control embryos vs embryos with ITLS are given below. Following the manufacture's instruction we prepared stock solutions in DMSO of Selumetinib, Pictilisib, and Vemurafenib in concentration of 100 mM, 50 mM, and 25 mM, respectively. Embryos were then exposed in 0.1 × MMR for the stages indicated to: Selumetinib −100 nMm, Pictillisib −1 μM, and Vemurafenib −1 μM. All three compounds were obtained from Selleckchem.